We use cookies to make your visit to our website as pleasant as possible. If you continue to use the website, you agree to our privacy policy and to the use of cookies. More information about cookies and how ImpediMed uses them is available in our Cookie and Privacy Policy.
Accept Cookies

BIS vs Other Methods for Early Lymphedema Detection

How bioimpedance spectroscopy (BIS) compares to MF-BIA, perometry, tape measure, and tissue dielectric constant — across guidelines, evidence, FDA status, and reimbursement.

Powered by BIS

Smiling woman with shoulder-length brown hair in a circular headshot, wearing a blue top, dark background.In NCCN & NAPBC standards
Smiling woman with shoulder-length brown hair in a circular headshot, wearing a blue top, dark background.Level I evidence (PREVENT)
Smiling woman with shoulder-length brown hair in a circular headshot, wearing a blue top, dark background.FDA-cleared for lymphedema

How the Methods Compare, at a Glance

BIS is the only method meeting all six clinical criteria compared here.

Clinical Criterion BIS MF-BIA
(InBody)		 Tissue
Dielectric		 Perometry LymphaTech
3D		 Tape
Measure
Screening in NCCN Survivorship Guidelines1 Yes. No No Yes. No No
Lymphedema prevention in NAPBC Standards2 Yes. No No No No No
Detects subclinical lymphedema (ASBrS)3 Yes. No No No No No
Level I randomized data, early intervention4 Yes. No No No No Yes.
FDA-cleared for lymphedema assessment5,6 Yes. No Yes. No No No

Yes. Meets criterion   No Does not/Not indicated.

*FDA clearance for tissue dielectric constant devices is specific to those products’ cleared indications.

What Each Method Actually Measures

Detection methods differ by target: fluid, tissue water, or limb volume. Only fluid-based BIS catches the change that comes first.

 

FLUID ASSESSMENT
RECOMMENDED

Bioimpedance Spectroscopy (BIS)

256 frequencies + Cole analysis isolate extracellular fluid to detect subclinical change. Generates the L-Dex score on SOZO.

What is BIS?

Multi-Frequency BIA (InBody)

Body composition analyzers using a few frequencies. Not cleared for the clinical assessment of lymphedema.

TISSUE CONTENT

Tissue Dielectric Constant

MoistureMeter D and LymphScanner measure local skin-surface water rather than whole-limb fluid.

VOLUME ASSESSMENT

Perometry

Infrared limb-volume measurement. Detects size change, not the fluid shift that precedes it.

LymphaTech 3D

3D scanning to estimate limb volume as an alternative to manual measurement.

Tape Measure

Manual circumference converted to volume. Detects change only once swelling is measurable.

What BIS Delivers on SOZO

BIS powers the L-Dex® score — a lymphedema-specific measure tracked against each patient’s baseline.

92%

reduction in lymphedema progression with BIS-guided early intervention.⁴

80%

sensitivity for subclinical unilateral lymphedema.⁹

90%

specificity for subclinical unilateral lymphedema.⁹

BIS vs MF-BIA: The Technical Difference

Both are bioimpedance, but built for different jobs — early fluid detection vs. whole-body composition. For how BIS works, see What is BIS?

Capability ImpediMed BIS MF-BIA (InBody)
Frequencies measured 256 2-6*
Frequency range 3-1,000 kHz 1-1,100 kHz
Frequencies used for fluid volumes 256 2-3*
Cole analysis Yes No
Automated measurement quality Yes No6
FDA-cleared for lymphedema assessment Yes No7
FDA-cleared for unhealthy populations Yes No

*Frequency range and frequencies measured vary by manufacturer and model. MF-BIA analyzers have very limited BCRL clinical data (level 3 evidence at best).5

The Evidence Behind BIS

BIS is named across the major breast cancer survivorship standards and backed by randomized data.

NCCN Guidelines1

Lists bioimpedance spectroscopy among objective tools for early lymphedema surveillance (SLYMPH-3).

NAPBC Standards2

Standard 5.15 supports objective measurement such as BIS within a lymphedema prevention program.

ASBrS Working Group3

Reviewed work notes BIS can detect subclinical lymphedema before it is clinically visible.

PREVENT Trial4

The largest randomized trial to assess lymphedema prevention — Level I evidence for BIS-guided early intervention.

Frequently Asked Questions

FAQs

Is BIS FDA-cleared for lymphedema assessment?

Yes. SOZO is FDA-cleared for the clinical assessment of lymphedema (510(k) K180126).⁵,⁶ MF-BIA body composition analyzers such as InBody are not.⁷

What is the difference between BIS and BIA?

BIS measures 256 frequencies and applies Cole analysis to isolate extracellular fluid, the marker of early lymphedema. MF-BIA samples only a few frequencies for body composition and does not perform Cole analysis or automated quality grading. Learn more about BIS

How accurate is BIS for detecting lymphedema?

The L-Dex score is reported as 80% sensitive and 90% specific for subclinical unilateral lymphedema, using a threshold of +6.5 points from baseline.⁴,⁹

BIS vs perometry vs tape measure — which detects lymphedema earliest?

Perometry and tape measure detect volume change only once swelling is measurable. BIS detects the earlier extracellular-fluid shift and is the only method here specified for NCCN screening, included in NAPBC standards, and supported by Level I evidence for early intervention.

What is L-Dex?

L-Dex is a proprietary index from BIS measurements on SOZO. It tracks fluid change in an at-risk limb against the patient’s baseline, enabling detection before lymphedema is clinically visible.

Request Demo

References

  1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Survivorship V.2.2025. © NCCN, Inc. 2025. All rights reserved. Accessed June 12, 2025. See NCCN.org for the most recent version. NCCN makes no warranties regarding their content, use, or application.
  2. Used with permission of the American College of Surgeons, Chicago, Illinois. Content does not reflect the views or interpretations of the American College of Surgeons.
  3. McEvoy MP, et al. The prevention and treatment of breast cancer related lymphedema: A review. Frontiers in Oncology, 2022.
  4. Ridner SH, et al. A Comparison of Bioimpedance Spectroscopy or Tape Measure Triggered Compression Intervention in Chronic Breast Cancer Lymphedema Prevention. Lymphatic Research and Biology, 2022.
  5. Research Database, InBody Scholar (Feb 8, 2024), InBody USA. / BIS FDA 510(k) Clearance K180126, April 2018.
  6. MoistureMeter D Compact, LymphScanner FDA 510(k) Clearance K220557, May 2022. / K180126 SOZO® Regulation, 21 CFR § 870.2770, FDA, August 11, 2017.
  7. K141483 Biospace Body Composition Analyzers (InBody770, 570, S10, 230), FDA, September 23, 2014.
  8. Current Procedural Terminology (CPT®) Professional Edition 2023. Copyright 2023 American Medical Association. CPT is a registered trademark of the AMA.
  9. Fu MR, et al. L-Dex ratio in detecting breast cancer-related lymphedema: reliability, sensitivity, and specificity. Lymphology 2013;46:85–96. NCCN = National Comprehensive Cancer Network® (NCCN®).